Search Result

Results for "

H3K9me2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adrenergic Receptor (1) Amyloid-β (1) Androgen Receptor (1) Apoptosis (10) ATP Synthase (3) Autophagy (5) Bcl-2 Family (1) Caspase (1) DNA Methyltransferase (2) EGFR (1) Endogenous Metabolite (3) GCGR (1) GLP Receptor (2) Glucocorticoid Receptor (1) GSK-3 (1) Histone Demethylase (5) Histone Methyltransferase (27) Microtubule/Tubulin (1) mTOR (3) PROTACs (3) Reactive Oxygen Species (ROS) (4) Reference Standards (5) STAT (1) Tau Protein (1) Wee1 (1)
By Research Areas:	Cancer (30) Inflammation/Immunology (4) Metabolic Disease (1) Neurological Disease (7)

By Targets:

Adrenergic Receptor (1)

Amyloid-β (1)

Androgen Receptor (1)

Apoptosis (10)

ATP Synthase (3)

Autophagy (5)

Bcl-2 Family (1)

Caspase (1)

DNA Methyltransferase (2)

EGFR (1)

Endogenous Metabolite (3)

GCGR (1)

GLP Receptor (2)

Glucocorticoid Receptor (1)

GSK-3 (1)

Histone Demethylase (5)

Histone Methyltransferase (27)

Microtubule/Tubulin (1)

mTOR (3)

PROTACs (3)

Reactive Oxygen Species (ROS) (4)

Reference Standards (5)

STAT (1)

Tau Protein (1)

Wee1 (1)

By Research Areas:

Cancer (30)

Inflammation/Immunology (4)

Metabolic Disease (1)

Neurological Disease (7)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10587

BIX-01294 Maximum Cited Publications 27 Publications Verification	Histone Methyltransferase Autophagy	Cancer
BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .

HY-13808

UNC 0631 5 Publications Verification	Histone Methyltransferase	Cancer
UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces *H3K9me2* levels in MDA-MB-231 cells with an IC₅₀ of 25 nM .

HY-100542

D-α-Hydroxyglutaric acid disodium 4 Publications Verification Disodium (R)-2-hydroxyglutarate	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113038

D-α-Hydroxyglutaric acid 4 Publications Verification (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-152775

RK-701	Histone Methyltransferase	Cancer
RK-701 is an highly selective and non-genotoxic inhibitor of G9a with IC₅₀ value of 23-27 nM. RK-701 selectively up-regulates HbF, γ- Globin, BGLT3 expression, down-regulates H3K9me2 expression. RK-701 also has inhibition for BCL11A and ZBTB7A .

HY-101925

CM-272 3 Publications Verification	Histone Methyltransferase DNA Methyltransferase Apoptosis	Cancer
CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC₅₀s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death .

HY-13807

UNC0646 1 Publications Verification	Histone Methyltransferase	Cancer
UNC0646 is a potent and selective histone methyltransferase G9a inhibitor with an IC₅₀ of 6 nM. UNC0646 is also a potent GLP inhibitor (IC₅₀ <15 nM) and highly selective for G9a/GLP over SETD7, SUV39H2, SETD8 and PRMT3. UNC0646 reduces *H3K9me2* levels in MDA-MB-231 cells with an IC₅₀ of 26 nM .

HY-162275

JMJD1C-IN-1	Histone Demethylase Histone Methyltransferase STAT	Cancer
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC₅₀ = 0.59 μM, K_d = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC₅₀ = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting *H3K9me2* accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .

HY-13808R

UNC 0631 (Standard)	Reference Standards Histone Methyltransferase	Cancer
UNC 0631 (Standard) is the analytical standard of UNC 0631. This product is intended for research and analytical applications. UNC 0631 is a potent histone methyltransferase G9a inhibitor with an IC₅₀ of 4 nM. UNC 0631 potently reduces *H3K9me2* levels in MDA-MB-231 cells with an IC₅₀ of 25 nM .

HY-10930

UNC0321 2 Publications Verification	Histone Methyltransferase GCGR Apoptosis	Cancer
UNC0321 is a potent and selective histone methyltransferase G9a inhibitor with a K_i of 63 pM and with assay-dependent IC₅₀ values of 6-9 nM. UNC0321 also inhibits GLP with assay-dependent IC₅₀ values of 15-23 nM. UNC0321 has anti-apoptotic activity and has potential application in diabetic vascular complications .

HY-162749A

G9D-4 TFA	PROTACs Histone Methyltransferase Apoptosis	Cancer
G9D-4 TFA is a G9a PROTAC degrader. G9D-4 TFA induces G9a degradation, reduces *H3K9me2* levels, and prevents GLP interference via the CRBN ternary complex, proteasome and ubiquitin-like modification-dependent pathways. G9D-4 TFA exerts antiproliferative activity and induces Apoptosis in pancreatic cancer cells. G9D-4 TFA can be used for research on pancreatic cancer .

HY-108239

BIX-01294 trihydrochloride Maximum Cited Publications 27 Publications Verification	Histone Methyltransferase Autophagy	Cancer
BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .

HY-156285

ZZM-1220	Histone Methyltransferase Apoptosis	Cancer
ZZM-1220 is a histone lysine methyltransferase G9a/GLP covalent inhibitor with IC₅₀s of of 458 nM and 924 nM, respectively. ZZM-1220 inhibits H3K9me2 in cells and significantly induces apoptosis of triple-negative breast cancer (TNBC) cells and blocks the cell cycle in the G2/M phase .

HY-150510

MS8511	Histone Methyltransferase	Neurological Disease Cancer
MS8511 is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC₅₀ values of 100 nM (G9a) and 140 nM (GLP), and K_d values of 44 nM (G9a) and 46 nM (GLP). MS8511 reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .

HY-44062

G9a-IN-1	Histone Methyltransferase	Inflammation/Immunology Cancer
G9a-IN-1 (Compound 113) is a G9a protein inhibitor. G9A/EHMT2 is a nuclear histone lysine methyltransferase that catalyzes histone H3 lysine 9 dimethylation (H3K9me2), which is a reversible modification generally associated with transcriptional gene silencing. G9a-IN-1 can be used for the research of autoimmune disorders or cancer .

HY-162749

G9D-4	PROTACs Histone Methyltransferase Apoptosis	Cancer
G9D-4 is a G9a PROTAC degrader. G9D-4 induces G9a degradation, reduces *H3K9me2* levels, and prevents GLP interference via the CRBN ternary complex, proteasome and ubiquitin-like modification-dependent pathways. G9D-4 exerts antiproliferative activity and induces Apoptosis in pancreatic cancer cells. G9D-4 can be used for research on pancreatic cancer .

HY-168992

UNC6535	Histone Methyltransferase	Neurological Disease Cancer
UNC6535 is a covalent ligand targeting the SETDB1 triple Tudor domain (3TD) with negative allosteric modulator properties, with an IC₅₀ of 3.4 μM and a K_d of 4.2 μM. UNC6535 inhibits the methyltransferase activity of recombinant SETDB1 protein lacking the 3TD domain. UNC6535 reversibly binds to the aromatic cages of both TD2 and TD3 subdomains of SETDB1 3TD simultaneously, displacing the endogenous H3K9Me2K14Ac histone tail ligand. UNC6535 can be used in research on cancer and neurodegenerative diseases .

HY-150510A

MS8511 hydrochloride	Histone Methyltransferase	Neurological Disease Cancer
MS8511 (hydrochloride) is a selective G9a/GLP covalent irreversible inhibitor by targeting a cysteine residue at the substrate binding site, with IC₅₀ values of 100 nM (G9a) and 140 nM (GLP), and K_d values of 44 nM (G9a) and 46 nM (GLP). MS8511 (hydrochloride) reduces the cellular H3K9me2 level and enhances antiproliferation activity. MS8511 (hydrochloride) can be used for the research of several types of cancers including brain, breast, ovarian, lung, bladder, melanoma, colorectal cancer, and other disease such as Alzheimer’s disease (AD), sickle cell disease, Prader−Willi syndrome (PWS) .

HY-178065

PROTAC G9a/GLP degrader 1	PROTACs Histone Methyltransferase GLP Receptor	Cancer
PROTAC G9a/GLP degrader 1 is a G9a/GLP PROTAC degrader with DC₅₀s of 336 nM (G9a) and 988 nM (GLP). PROTAC G9a/GLP degrader 1 exhibits inhibitory activity against G9a with an IC₅₀ of 98 nM. PROTAC G9a/GLP degrader 1 effectively inhibits the migration of breast cancer MCF-7 cells without inhibiting cell proliferation. PROTAC G9a/GLP degrader 1 can be used for the study of breast cancer (Pink: G9a/GLP ligand (HY-152775); Blue: VHL ligand (HY-125845); Black: Linker (HY-140468)) .

HY-116971

DCG066	Histone Methyltransferase Apoptosis	Cancer
DCG066 is an inhibitor of lysine methyltransferase G9a. DCG066 can bind directly to G9a and inhibit methyltransferase activity in vitro. DCG066 decreases di-methylation levels of histone H3 lysine 9 (H3K9Me2), inhibits cell proliferation and induces cell apoptosis. DCG066 displays low cytotoxicity in leukemia cell lines with high levels of G9a expression, including K562 .

HY-178378

G9a-IN-4	Histone Methyltransferase GLP Receptor Reactive Oxygen Species (ROS) Autophagy Apoptosis	Cancer
G9a-IN-4 is a G9a inhibitor with high selectivity (IC₅₀ = 32 nM). G9a-IN-4 shows high selectivity against the other tested lysine/arginine methyltransferases. G9a-IN-4 exhibits high enzymatic activity against G9a and more potent antiproliferative effects against all tested cancer cells. G9a-IN-4 significantly suppresses the H3K9me2 level. G9a-IN-4 triggers autophagy by inducing the production of ROS, thus leading to cell apoptosis and cell cycle arrest at G0/G1 in CT26 colon cells. G9a-IN-4 can be used for the study of colon cancer .

HY-176283

Tubulin/LSD1-IN-1	Microtubule/Tubulin Histone Demethylase Apoptosis Wee1 Bcl-2 Family Caspase	Cancer
Tubulin/LSD1-IN-1 is an effective dual inhibitor of Tubulin polymerization and LSD1 (IC₅₀ = 1.72 μM). Tubulin/LSD1-IN-1 has broad-spectrum antiproliferative activity against cancer cell lines. Tubulin/LSD1-IN-1 inhibits tubulin polymerization by targeting colchicine binding sites, thereby disrupting the microtubule network in gastric cancer cells. Tubulin/LSD1-IN-1 increases the methylation levels of H3K4me1/2 and H3K9me2/3, thereby achieving epigenetic regulation. Tubulin/LSD1-IN-1 induces G2/M arrest, promotes apoptosis, and effectively inhibits colony formation of gastric cancer cells .

HY-161787

G9a-IN-2	Histone Methyltransferase	Others
G9a-IN-2 (Compound 7i) is an inhibitor for histone methyltransferases G9a with IC₅₀ of 0.024 μM. G9a-IN-2 reduces H3K9me2 levels and induces the mRNA expression of γ-globin mRNA. G9a-IN-2 shows the potential in ameliorating sickle cell disease (SCD) .

HY-168968S

ZJY-54	EGFR Histone Demethylase	Cancer
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC₅₀ values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity .

HY-183058

EZM8266	Histone Methyltransferase	Cancer
EZM8266 is an orally active and selective G9a (EHMT2) histone methyltransferase inhibitor with a human EHMT2 IC₅₀ of 1 pM. EZM8266 reduces repressive H3K9me2 marks at immune-stimulatory gene and endogenous retroviral element promoters. EZM8266 reduces colony formation, migration, and invasion of cancer cells. EZM8266 enhances IFN-γ response, increases MHC class I expression, and enhances CXCL10-mediated T cell recruitment in cancer cells. EZM8266 can be used for the research of hepatocellular carcinoma .

HY-152775A

RK-0133114	Histone Methyltransferase	Metabolic Disease
RK-0133114 is a G9a inhibitor and a R-enantiomer of RK-701 (HY-152775). RK-0133114 inhibits G9a with an IC₅₀ value of 3.7 μM. RK-0133114 can be used for the research of sickle cell disease (SCD) .

HY-168504

LSD1-IN-36	Histone Demethylase Apoptosis	Cancer
LSD1-IN-36 is a potent LSD1 inhibitor with an IC₅₀ value of 0.8 nM. LSD1-IN-36 induces apoptosis and arrests the cell cycle. LSD1-IN-36 shows antitumor activity .

HY-100542R

D-α-Hydroxyglutaric acid disodium (Standard) Disodium (R)-2-hydroxyglutarate (Standard)	Reference Standards Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite	Neurological Disease Inflammation/Immunology Cancer
D-α-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of D-α-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-115747

Namoline	Histone Demethylase	Cancer
Namoline, a γ-pyrone, is a selective and reversible Lysine-specific demethylase 1 (LSD1) inhibitor with an IC50 of 51 μM in a HRP-coupled enzymatic assay. Namoline impairs LSD1 demethylase activity and blocks cell proliferation. Namoline has the potential for androgen-dependent prostate cancer research .

HY-W657887

GSK-3β/G9a-IN-1	Histone Methyltransferase GSK-3 Tau Protein Amyloid-β Glucocorticoid Receptor Androgen Receptor Adrenergic Receptor	Neurological Disease
GSK-3β/G9a-IN-1 (Compound T2) is an orally active, selective, blood-brain-barrier permeable, competitive G9a (substrate-competitive, IC₅₀: 1.1 μM) and GSK-3β (ATP competitive, IC₅₀: 0.8 μM) inhibitor. GSK-3β/G9a-IN-1 is a potent *H3K9me2* inhibitor that reshapes chromatin landscape. GSK-3β/G9a-IN-1 lowers tau phosphorylation, reduces Aβ aggregation. GSK-3β/G9a-IN-1 displays inhibition toward glucocorticoid receptor, androgen receptor, and alpha-2A adrenergic receptor. GSK-3β/G9a-IN-1 also upregulates SAGA complex members such as Eny2 and Sgf29. GSK-3β/G9a-IN-1 markedly improves memory, restores social behaviors, and increases synaptic complexity in late-onset Alzheimer’s disease .

HY-168992A

UNC6535 TFA	Histone Methyltransferase	Others
UNC6535 TFA is a covalent ligand targeting the triple Tudor domain (3TD) of SETDB1. UNC6535 TFA reversibly binds to the aromatic cages of both TD2 and TD3 within SETDB1 3TD simultaneously, weakly inhibits the methyltransferase activity of SETDB1, and displaces the H3K9Me2K14Ac peptide from SETDB1 3TD .

HY-10587R

BIX-01294 (Standard)	Reference Standards Histone Methyltransferase Autophagy	Cancer
BIX-01294 (Standard) is the analytical standard of BIX-01294 (HY-10587). This product is intended for research and analytical applications. BIX-01294 is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 has antitumor activity in recurrent tumor cells .

HY-108239R

BIX-01294 trihydrochloride (Standard)	Reference Standards Histone Methyltransferase Autophagy	Cancer
BIX-01294 trihydrochloride (Standard) is the analytical standard of BIX-01294 (trihydrochloride) (HY-108239). This product is intended for research and analytical applications. BIX-01294 trihydrochloride is a reversible and highly selective G9a and GLP Histone Methyltransferase inhibitor, with IC₅₀s of of 1.7 μM and 0.9 μM, respectively. BIX-01294 trihydrochloride inhibits G9a/GLP by competing for binding with the amino acids N-terminal of the substrate lysine residue. BIX-01294 trihydrochloride, a (1H-1,4-diazepin-1-yl)-quinazolin-4-yl amine derivative, induces necroptosis and autophagy. BIX-01294 trihydrochloride has antitumor activity in recurrent tumor cells .

HY-101925R

CM-272 (Standard)	Reference Standards Histone Methyltransferase DNA Methyltransferase Apoptosis	Cancer
CM-272 (Standard) is the analytical standard of CM-272 (HY-101925). This product is intended for research and analytical applications. CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC₅₀s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-100542

D-α-Hydroxyglutaric acid disodium 4 Publications Verification Disodium (R)-2-hydroxyglutarate	Structural Classification Human Gut Microbiota Metabolites Classification of Application Fields Ketones, Aldehydes, Acids Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification Cancer	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-113038

D-α-Hydroxyglutaric acid 4 Publications Verification (R)-2-Hydroxyglutarate; (R)-2-Hydroxyglutaric acid; (R)-2-Hydroxypentanedioic acid	Classification of Application Fields Neurological Disease Anti-aging Endocrine diseases Endogenous metabolite Immune System Disorder Ketones, Aldehydes, Acids Disease markers Nervous System Disorder Disease Research Fields Inflammation/Immunology Cancer Source Classification	Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid ((R)-2-Hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a K_i of 10.87 mM. D-α-Hydroxyglutaric acid increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid binds and inhibits ATP synthase and inhibits mTOR signaling .

HY-100542R

D-α-Hydroxyglutaric acid disodium (Standard) Disodium (R)-2-hydroxyglutarate (Standard)	Structural Classification Human Gut Microbiota Metabolites Ketones, Aldehydes, Acids Endogenous metabolite Source Classification	Reference Standards Reactive Oxygen Species (ROS) ATP Synthase mTOR Endogenous Metabolite
D-α-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of D-α-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. D-α-Hydroxyglutaric acid disodium (Disodium (R)-2-hydroxyglutarate) is the principal metabolite accumulating in neurometabolic disease D-2-hydroxyglutaric aciduria. D-α-Hydroxyglutaric acid disodium is a weak competitive antagonist of α-ketoglutarate (α-KG) and inhibits multiple α-KG-dependent dioxygenases with a Ki of 10.87 mM. D-α-Hydroxyglutaric acid disodium increases reactive oxygen species (ROS) production. D-α-Hydroxyglutaric acid disodium binds and inhibits ATP synthase and inhibits mTOR signaling .

Cat. No.	Product Name	Chemical Structure

HY-168968S

ZJY-54
ZJY-54 is an orally active dual-target inhibitor of EGFR/LSD1, with IC₅₀ values of 3.8 nM and 0.6 μM, respectively. ZJY-54 can inhibit the proliferation of non-small cell lung cancer cells, induce the accumulation of H3K4me2 and H3K9me2, and inhibit the phosphorylation of the EGFR signaling pathway. ZJY-54 has anti-tumor activity .

Host:	Mouse (1) Rabbit (1)
Reactivity:	Human (2) Rat (2) Mouse (2)
Application:	IHC-P (2) ICC/IF (2) IF-Tissue (1) IP (1) WB (2) ChIP (1) ELISA (1)
Isotype:	IgG1 (1) IgG/Kappa (1)
Conjugation:	Non-conjugated (2)
Clonality:	Monoclonal (2)
Modification:	Methylated (2)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86148

	Histone H3 (Di Methyl Lys9) Antibody (YA5840) H3K9me2; HIST1H3A; H3FA; HIST1H3B; H3FL; HIST1H3C; H3FC; HIST1H3D; H3FB; HIST1H3E; H3FD; HIST1H3F; H3FI; HIST1H3G; H3FH; HIST1H3H; H3FK; HIST1H3I; H3FF; HIST1H3J; H3FJ; Histone H3.1; Histone H3/a; Histone H3/b; Histone H3/c; Histone H3/d; Histone H3/f; Histone H3/h; Histone H3/i; Histone H3/j; Histone H3/k; Histone H3/l; HIST2H3A; HIST2H3C; H3F2; H3FM; HIST2H3D; Histone H3.2; Histone H3/m; Histone H3/o; H3F3A; H3.3A; H3F3; PP781; H3F3B; H3.3B; Histone H3.3	WB, IHC-P, ICC/IF, IP, ChIP, ELISA	Human, Mouse, Rat
	Histone H3 (Di Methyl Lys9) Antibody (YA5840) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Histone H3 (Di Methyl Lys9).

HY-P80176

	Histone H3 (tri methyl K9) Antibody (YA734) H3K9me3; H3 histone family member E pseudogene; H3 histone family, memberA; H3/A; H31_HUMAN; H3F3; H3FA; Hist1h3a; HIST1H3B; HIST1H3C; HIST1H3D; HIST1H3E; HIST1H3F; HIST1H3G; HIST1H3H; HIST1H3I; HIST1H3J; HIST3H3; histone 1, H3a; Histone cluster 1, H3a; Histone H3 3 pseudogene; Histone H3.1; Histone H3/a; Histone H3/b; Histone H3/c; Histone H3/d; Histone H3/f; Histone H3/h; Histone H3/i; Histone H3/j; Histone H3/k; HistoneH3/l; H3K9me2; HistoneH3(trimethylK9)	WB, IHC-P, ICC/IF, IF-Tissue	Human, Mouse, Rat
	Histone H3 (tri methyl K9) Antibody (YA734) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Histone H3 (tri methyl K9).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks